THE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023
Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) inhibitor program expected in Q3 2022; IND expected in 2023
Read more at prnewswire.com